References

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

10.3322/caac.21834 · 2024 · External reference

Molecular therapies and precision medicine for hepatocellular carcinoma

10.1038/s41571-018-0073-4 · 2018 · External reference

Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

10.1016/j.jhep.2021.11.030 · 2022 · External reference

Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

10.1056/evidoa2100070 · 2022 · External reference

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

10.1016/s0140-6736(23)00961-3 · 2023 · External reference

Immunotherapies for hepatocellular carcinoma

10.1038/s41571-021-00573-2 · 2022 · External reference

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

10.1038/s41591-022-01868-2 · 2022 · External reference

Glypican-3: a new target for diagnosis and treatment of hepatocellular carcinoma

10.7150/jca.39972 · 2020 · External reference

Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials

10.1158/1078-0432.ccr-19-3259 · 2020 · External reference

Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial

10.1080/2162402x.2020.1846926 · 2020 · External reference

RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial

10.1016/j.eclinm.2023.102175 · 2023 · External reference

Shed antigen-induced blocking effect on CAR-T cells targeting glypican-3 in hepatocellular carcinoma

10.1136/jitc-2020-001875 · 2021 · External reference

Comparison of T Cell activities mediated by human TCRs and CARs that use the same recognition domains

10.4049/jimmunol.1700236 · 2018 · External reference

Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma

10.1016/j.jhep.2019.12.014 · 2020 · External reference

Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA

1999 · External reference

Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumors

10.1016/j.omto.2022.04.003 · 2022 · External reference

Integrated analysis of multimodal single-cell data

10.1016/j.cell.2021.04.048 · 2021 · External reference

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

10.1038/s41591-020-1061-7 · 2020 · External reference

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

10.1136/jitc-2022-005920 · 2023 · External reference

Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers

10.1038/s41586-024-08261-8 · 2025 · External reference

Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)

10.1200/jco.2024.42.16_suppl.4019 · 2024 · External reference

From TCR fundamental research to innovative chimeric antigen receptor design

10.1038/s41577-024-01093-7 · 2025 · External reference

Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond

10.1038/s41423-025-01304-8 · 2025 · External reference

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s0140-6736(16)32453-9 · 2017 · External reference

Cabozantinib in patients with advanced and progressing hepatocellular carcinoma

10.1056/nejmoa1717002 · 2018 · External reference

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s1470-2045(18)30937-9 · 2019 · External reference

Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial

10.1200/jco.19.01307 · 2020 · External reference

Assessment of cancer cell-expressed HLA class I molecules and their immunopathological implications

10.1111/tan.15472 · 2024 · External reference

Phase I study of Ori-C101, an armored GPC3-directed CAR-T, in patients with advanced hepatocellular carcinoma (HCC)

10.1200/jco.2025.43.16_suppl.4084 · 2025 · External reference

IL-6: the link between inflammation, immunity and breast cancer

10.3389/fonc.2022.903800 · 2022 · External reference

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

10.1016/j.ccell.2022.04.004 · 2022 · External reference

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

10.1038/s41591-018-0010-1 · 2018 · External reference

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

10.1172/jci24480 · 2005 · External reference

The interplay between membrane topology and mechanical forces in regulating T cell receptor activity

10.1038/s42003-021-02995-1 · 2022 · External reference

The affinity of elongated membrane-tethered ligands determines potency of T cell receptor triggering

10.3389/fimmu.2017.00793 · 2017 · External reference

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness

10.1136/jitc-2021-002866 · 2021 · External reference

Dynamics of immune reconstitution and impact on outcomes across CAR-T cell products in large B-cell lymphoma

10.1158/2643-3230.bcd-24-0163 · 2025 · External reference

Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review

10.1007/s12672-025-03138-2 · 2025 · External reference

Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire

10.1038/s41467-025-59904-x · 2025 · External reference

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma

10.1126/scitranslmed.abc3196 · 2021 · External reference

Immunogenicity of CAR T cells in cancer therapy

10.1038/s41571-021-00476-2 · 2021 · External reference